111In- Capromab Studies:
Study	Agent used	Number of patients	Type of patient population	Result	Comments
Sodee DB et al [38]	111In- 7E11	15	Localized residual or metastatic PC post prostatectomy and lymphadenectomy with rising serum PSA. All patients had negative pre- study radiographic abdominal and pelvic cross-sectional images.	One patient with low PSA had normal imaging results and 14 patients had scintigraphic evidence of residual prostatic bed or metastatic prostatic carcinoma. Two patients with borderline abnormal bone scans had abnormal activity in the same regions on capromab
Deb N et al [39]	111In &90Y- CYT356	12	CRPC	Myelosuppression was the dose-limiting toxicity. No patient attained a complete or partial response based on PSA and/or radiological criteria.	Patients treated on higher dose of 90Y-CYT356 had greater progression free survival
Manyak MJ et al [40]	111In- 7E11	152	High pre-surgical PSA, high Gleason score/clinical stage	Capromab scans showed a sensitivity of 62%, sensitivity of 72%, PPV of 62%, NPV of 2% and an overall accuracy of 68%. In comparison, CT had sensitivity of 4% and specificity of 100%.	Improved visualization of these scintigraphic findings by improved radiotracer detection or a mAb affinity increase the relevance of PSMA imaging.
Kahn et al [41]	111In- 7E11	32	Residual biochemical evidence of disease after radical prostatectomy	Capromab scans demonstrated metastasis in 9/32 (28%) with disseminated disease and 23/32 with local disease	The size of the cohorts and questions about how similar the groups of responders and non-responder were, continue to plague this study.
Levesque et al [42]	111In- CYT356	48	Recurrent PC detected by PSA following radical retropubic prostatectomy	The scans showed monoclonal uptake in pelvic, abdominal, and extrapelvic retroperitoneal sites beyond the region of limited obturator node dissections.	The study suggested a good predicting tool for selecting patients for salvage EBRT
Wilkensen et al [43]	111In- Capromab	42	Patients showing biochemical progression after radical prostatectomy.	42 patients underwent imaging for biochemical progression after radical prostatectomy. Abnormal accumulation of mAb was seen in 36 patients. Of these patients 16 (38.1%) subsequently completed a course of salvage RT.	A regular PSA screening in combination with 111In- Capromab imaging may result in significant improvement in rates of biochemical failure in PC patients
Thomas et al [44]		30	Patients who had 111In- Capromab scan and underwent salvage radiotherapy for recurrent disease after prostatectomy.	In patients who had prostatectomy and biochemical relapse and received salvage RT, presalvage RT In- Capromab scan findings outside the prostate fossa were not predictive of biochemical control after RT.